tiprankstipranks
Trending News
More News >
FMC Corp (FMC)
NYSE:FMC

FMC (FMC) AI Stock Analysis

Compare
1,573 Followers

Top Page

FMC

FMC

(NYSE:FMC)

Select Model
Select Model
Select Model
Neutral 47 (OpenAI - 4o)
Rating:47Neutral
Price Target:
$13.50
▲(2.43% Upside)
FMC's overall stock score reflects significant financial and operational challenges. The most impactful factors are the declining financial performance and bearish technical indicators. Valuation concerns with a negative P/E ratio and high dividend yield due to a cut further weigh on the score. Earnings call insights show mixed results with some positive developments overshadowed by major challenges. Potential impairment charges add to the risks.
Positive Factors
Strong Demand for New Products
The strong demand for new active ingredients indicates successful innovation and product development, which can drive future revenue growth and strengthen market position.
Adjusted EBITDA Improvement
Improved EBITDA reflects effective cost management and a favorable product mix, enhancing profitability and operational efficiency, crucial for long-term financial health.
Credit Agreement Amendment
The amended credit agreement provides financial flexibility and stability, allowing FMC to manage debt and invest in strategic initiatives over the long term.
Negative Factors
Revenue Decline
A significant revenue decline indicates challenges in maintaining market share and competitive pressures, which could impact long-term growth and profitability.
Free Cash Flow Challenges
Negative free cash flow limits the company's ability to reinvest in the business, pay down debt, or return capital to shareholders, affecting financial stability.
Dividend Reduction
A drastic dividend cut signals financial distress and may erode investor confidence, impacting the company's ability to attract and retain long-term shareholders.

FMC (FMC) vs. SPDR S&P 500 ETF (SPY)

FMC Business Overview & Revenue Model

Company DescriptionFMC Corporation, an agricultural sciences company, provides crop protection, plant health, and professional pest and turf management products. It develops, markets, and sells crop protection chemicals that include insecticides, herbicides, and fungicides; and biologicals, crop nutrition, and seed treatment products, which are used in agriculture to enhance crop yield and quality by controlling a range of insects, weeds, and diseases, as well as in non-agricultural markets for pest control. The company markets its products through its own sales organization and through alliance partners, independent distributors, and sales representatives. It operates in North America, Latin America, Europe, the Middle East, Africa, and Asia. FMC Corporation was founded in 1883 and is headquartered in Philadelphia, Pennsylvania.
How the Company Makes MoneyFMC generates revenue primarily through the sale of its agricultural products, which include crop protection chemicals and specialty solutions. The company operates through various segments, including the Crop Protection segment, which is its largest revenue contributor, offering a diverse portfolio of herbicides, insecticides, and fungicides. Additionally, FMC earns income from its Lithium segment, which supplies lithium compounds for electric vehicle batteries and other applications. Key revenue streams include direct sales to farmers, distributors, and agricultural retailers, along with strategic partnerships with agricultural organizations and collaborations with research institutions to enhance product development. The company's focus on innovation and sustainability also plays a crucial role in attracting customers and driving sales growth, as farmers increasingly seek environmentally friendly solutions to improve crop yields.

FMC Key Performance Indicators (KPIs)

Any
Any
Revenue by Geography
Revenue by Geography
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Chart InsightsFMC's revenue trends reveal strong growth in EMEA and Latin America, supported by higher herbicide sales and a successful growing season. However, North America and Asia face declines, exacerbated by destocking and competitive pressures in India, prompting a strategic divestment. Despite these regional challenges, FMC's focus on cost efficiencies and new product launches is expected to drive future growth, with a projected 14% increase in adjusted EBITDA for Q3 2025. Investors should watch for the impact of pricing pressures and FX headwinds on overall performance.
Data provided by:The Fly

FMC Earnings Call Summary

Earnings Call Date:Oct 29, 2025
(Q3-2025)
|
% Change Since: |
Next Earnings Date:Feb 04, 2026
Earnings Call Sentiment Neutral
The earnings call presented both positive outcomes such as strong demand for new active ingredients and EBITDA improvement, alongside significant challenges including a sharp revenue decline, particularly in Latin America, and a substantial dividend cut to manage cash flow issues.
Q3-2025 Updates
Positive Updates
Strong Demand for New Active Ingredients
Sales of new active ingredients nearly doubled compared to the prior year, demonstrating strong demand for technological innovations.
Adjusted EBITDA Improvement
Reported adjusted EBITDA of $236 million, 17% higher than prior year, driven by disciplined cost control and a favorable product mix.
Positive North America and EMEA Performance
Sales in North America and EMEA improved due to higher volumes and the launch of Isoflex active in Great Britain.
Negative Updates
Significant Revenue Decline
Reported third quarter GAAP net sales of $542 million, which is 49% lower than the prior year, majorly due to onetime actions in India.
Challenges in Latin America
Sales in Latin America lagged prior year by 8% due to constrained credit in Brazil and Argentina and pricing pressure from generics.
Free Cash Flow Challenges
Lowered free cash flow guidance to a range of negative $200 million to $0, impacted by collection delays and reduced liquidity.
Dividend Reduction
Board of Directors reduced the quarterly dividend by over 85% to $0.08 per share to redirect cash flow towards debt reduction.
Company Guidance
During the Third Quarter 2025 Earnings Call, FMC Corporation provided guidance reflecting challenging market conditions and strategic adjustments. The company reported adjusted EBITDA of $236 million with an EBITDA margin of approximately 25%, which was 17% higher on an as-reported basis and 23% higher on a like-for-like basis, excluding India. Adjusted earnings per share were $0.89, up 30% from the prior year. However, FMC lowered its full-year guidance, expecting revenue between $3.92 billion and $4.02 billion, with adjusted EBITDA between $830 million and $870 million. Free cash flow guidance was revised to a range of negative $200 million to $0. For the fourth quarter, the company anticipates sales, excluding India, to be between $1.12 billion and $1.22 billion, with adjusted EBITDA expected to be between $265 million and $305 million. These updates reflect ongoing pricing pressures, particularly from generics, and strategic cost actions to enhance competitiveness.

FMC Financial Statement Overview

Summary
FMC faces significant financial challenges, with declining revenues, profitability issues, and cash flow constraints. While the balance sheet shows some improvement in leverage, the negative ROE and cash flow problems highlight operational and financial risks. The company needs to address these issues to stabilize and improve its financial health.
Income Statement
45
Neutral
FMC's income statement shows a concerning trend with declining revenue and profitability. The TTM data reveals a significant drop in revenue by 13.95% and a negative net profit margin of -15.05%, indicating losses. Historical data shows a consistent decline in revenue growth and profitability margins, with gross profit margins decreasing over time. The EBIT and EBITDA margins have also deteriorated, reflecting operational challenges.
Balance Sheet
60
Neutral
The balance sheet presents a mixed picture. While the debt-to-equity ratio has improved to 0.34 in the TTM, indicating reduced leverage, the return on equity has turned negative, reflecting poor profitability. The equity ratio remains stable, suggesting a solid capital structure. However, the declining ROE and past high leverage pose potential risks.
Cash Flow
50
Neutral
Cash flow analysis highlights significant challenges. The TTM shows negative operating and free cash flows, with a substantial increase in free cash flow growth due to prior negative figures. The operating cash flow to net income ratio is negative, indicating cash flow issues. Despite a positive free cash flow to net income ratio, the overall cash flow position is weak.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue3.56B4.25B4.49B5.80B5.05B4.64B
Gross Profit1.31B1.58B1.91B2.39B2.19B2.07B
EBITDA254.30M737.40M786.20M1.30B1.19B1.04B
Net Income-534.90M339.90M1.32B736.50M739.60M552.40M
Balance Sheet
Total Assets12.08B11.65B11.93B11.17B10.67B10.19B
Cash, Cash Equivalents and Short-Term Investments497.70M357.30M302.40M572.00M516.80M568.90M
Total Debt4.54B3.50B4.11B3.42B3.34B3.44B
Total Liabilities8.28B7.14B7.49B7.77B7.53B7.20B
Stockholders Equity3.77B4.49B4.41B3.38B3.12B2.96B
Cash Flow
Free Cash Flow-409.40M603.20M-520.30M440.10M720.00M580.60M
Operating Cash Flow-317.50M671.10M-386.40M582.40M820.10M647.80M
Investing Cash Flow235.10M263.60M-154.40M-266.40M-112.00M-169.30M
Financing Cash Flow163.50M-870.10M331.50M-237.40M-747.90M-250.30M

FMC Technical Analysis

Technical Analysis Sentiment
Negative
Last Price13.18
Price Trends
50DMA
17.50
Negative
100DMA
26.48
Negative
200DMA
32.97
Negative
Market Momentum
MACD
-0.98
Negative
RSI
34.98
Neutral
STOCH
25.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FMC, the sentiment is Negative. The current price of 13.18 is below the 20-day moving average (MA) of 13.52, below the 50-day MA of 17.50, and below the 200-day MA of 32.97, indicating a bearish trend. The MACD of -0.98 indicates Negative momentum. The RSI at 34.98 is Neutral, neither overbought nor oversold. The STOCH value of 25.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FMC.

FMC Risk Analysis

FMC disclosed 37 risk factors in its most recent earnings report. FMC reported the most risks in the "Macro & Political" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

FMC Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
$12.08B9.4227.46%2.56%12.59%31.40%
65
Neutral
$7.72B6.3010.00%3.70%3.82%239.39%
61
Neutral
$10.43B7.12-0.05%2.87%2.86%-36.73%
60
Neutral
$6.56B18.126.15%3.36%1.77%-8.72%
50
Neutral
$3.44B23.614.52%-3.93%
47
Neutral
$1.65B-3.09-11.52%16.68%-13.42%-136.59%
28
Underperform
$272.09M-0.20-46.59%55.04%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FMC
FMC
13.13
-33.86
-72.06%
CF
Cf Industries Holdings
78.14
-5.25
-6.30%
MOS
Mosaic Co
24.29
0.76
3.23%
SMG
Scotts Miracle-Gro Company
58.39
-5.63
-8.79%
ICL
Icl
5.18
0.34
7.02%
USBC
USBC
0.71
-5.61
-88.77%

FMC Corporate Events

Financial Disclosures
FMC Faces Potential Non-Cash Impairment Charges
Negative
Dec 12, 2025

FMC Company is facing a significant decrease in its stock price, prompting it to test its goodwill and other intangible assets for impairment as per generally accepted accounting principles. This could lead to a substantial non-cash impairment charge, although it is not expected to affect the company’s cash flows from current or future operations.

Private Placements and FinancingBusiness Operations and Strategy
FMC Amends Credit Agreement, Extends Covenant Relief
Neutral
Dec 9, 2025

On December 8, 2025, FMC Corporation and its subsidiaries entered into an amendment to their credit agreement, which modifies financial covenants and extends the covenant relief period to December 31, 2028. The amendment imposes limits on subsidiary indebtedness and dividend increases, and requires maintaining a minimum value of intellectual property, with provisions for asset liens if credit ratings fall below specified levels.

Executive/Board Changes
FMC Board Member Anthony DiSilvestro Resigns
Neutral
Dec 3, 2025

On December 3, 2025, Anthony DiSilvestro resigned from FMC Corporation’s Board of Directors and all its committees due to increased professional commitments and scheduling conflicts after becoming the Chief Financial Officer of Keurig Dr Pepper Inc. on November 25, 2025. FMC expressed gratitude for his service and contributions during his tenure on the Board.

Executive/Board Changes
FMC Announces President Ronaldo Pereira’s Departure
Neutral
Oct 29, 2025

On October 29, 2025, FMC Corporation announced that Ronaldo Pereira will step down as President effective December 15, 2025, after 28 years with the company. Pereira, a veteran in the crop protection industry, has significantly impacted FMC’s operations in Latin America and North America. He will remain in an advisory role until his departure to ensure a smooth transition.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 13, 2025